December 13, 2016 / 1:22 PM / 7 months ago

BRIEF-Dimension Therapeutics says FDA acceptance of investigational NDA for DTX301

1 Min Read

Dec 13 (Reuters) - Dimension Therapeutics Inc

* Dimension Therapeutics - anticipates commencing multi-center Phase 1/2 clinical trial to evaluate DTX301 in patients with OTC deficiency by end of 2016

* Dimension Therapeutics announces FDA acceptance of investigational New Drug Application for DTX301 to treat otc deficiency Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below